Michael Joseph DiGiovanna DO

Family Medicine•Massapequa, NY

Chief, Division of Medicine, New York Health Divisional Chief of Primary Care, DiGiovanna Family Health & Wellness Center

Join to View Full Profile

1061 North Broadway2nd floorMassapequa, NY 11758
Phone+1 516-420-4300
Fax+1 516-420-0730

Education & Training

NYC Health & Hospitals/South Brooklyn HealthInternship, Transitional Year, 1987 - 1988
NYIT College Of Osteopathic MedicineClass of 1987

Certifications & Licensure

NY State License 1988 - 2026
AOA Board of Family PhysiciansFamily Practice and Osteopathic Manipulative Medicine

Clinical Trials

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) Start of enrollment: 2005 Mar 01
Completed
Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy Start of enrollment: 2005 Jul 01
Completed
Phase 3
A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes Mellitus Start of enrollment: 2005 Jun 01
Completed
Phase 2
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Start of enrollment: 2006 Oct 04
Completed
Phase 4
Amphotericin B Suspension in Refractory Chronic Sinusitis Start of enrollment: 2006 Dec 01
Completed
Phase 3
Study of CB-183,315 in Participants With Clostridium Difficile Infection Start of enrollment: 2010 Apr 01
Completed
Phase 2
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Start of enrollment: 2010 Jul 01
Completed
Phase 3
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication Start of enrollment: 2010 Oct 01
Completed
Phase 3
Cardiovascular Inflammation Reduction Trial Start of enrollment: 2013 Apr 01
Completed
Phase 3
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes Start of enrollment: 2012 Jun 01
Completed
Phase 3
Longitudinal Study of Patients With Opioid-Induced Constipation Start of enrollment: 2012 Oct 01
Completed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis Start of enrollment: 2024 Mar 29
RECRUITING
PHASE2
Roles: Principal Investigator
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease Start of enrollment: 2024 Mar 05
RECRUITING
PHASE2
Roles: Principal Investigator
Join now to see all

Press Mentions

Neelma Khan, MD Joins New York HealthAugust 3rd, 2021

Professional Memberships

Other Languages

Spanish, German, Hindi, Urdu, Italian, Punjabi, Russian

Industry Relationships

Researcher, AstraZeneca